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 There are multiple surgical procedures that require vascular or microvascular 
anastomosis; some of which include free tissue transfer for soft tissue reconstruction, 
vascular grafts and bypass surgeries. The two most common complications with a 
procedure involving vascular anastomosis are thrombosis and stenosis. The current 
method to prevent anastomotic thrombosis is the use of an anti-coagulant such as heparin. 
Heparin has also shown to reduce vascular smooth muscle cell proliferation which is an 
initiating factor for intimal hyperplasia and ultimately, stenosis. Another well-known 
treatment for stenosis prevention in vascular injuries is the anti-proliferative drug, 
paclitaxel. Previously in our 4D lab, we have fabricated and characterized heparin-
immobilized electrospun sutures to prevent coagulation after vascular anastomosis. The 
objective of this project is to develop an electrospun paclitaxel-eluting suture 
incorporating a novel, amphiphilic block copolymer, polyethylenimine-g-poly (D, L-
lactide-co-glycolide) (PgP), which we have synthesized in our 4D lab, in order to prevent 
the proliferation of vascular smooth muscle cells (VSMCs) after anastomosis procedures. 
We hypothesize that paclitaxel, a hydrophoboic molecule and anti-proliferative drug, will 
bind to the hydrophobic block of our copolymer. Adding this novel copolymer into the 
suture is expected to provide sustained and controlled release of paclitaxel in order to 
prevent stenosis. We have already successfully immobilized heparin onto the electrospun 
fibers and assessed the release kinetics and therapeutic activity in-vitro. In this study, we 
incorporated paclitaxel into the electrospun fiber composition and evaluated 
physicochemical properties of the paclitaxel loaded electrospun fiber yarns, paclitaxel 
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loading efficiency, release kinetics and therapeutic activity in-vitro. In the future, we will 
combine both heparin and paclitaxel into the fiber and evaluate the therapeutic effect of 
the dual-drug loaded electrospun suture in a rat vein anastomosis model in vivo as well as 
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CHAPTER 1 – INTRODUCTION 
 
1.1 Sutures 
As a general definition, a suture is a strand of material used to ligate or re-connect 
tissue. [1] Sutures are the most widely used medical device in surgical procedures 
capturing over a billion-dollar annual market. There are more than 5,000 varieties of 
sutures available that range in natural versus synthetic composition, absorbable versus 
non-absorbable, monofilament versus multi-filament and size. [1,2] There are pros and 
cons to each of these characteristics that a surgeon can use to decide which type is 
appropriate for the procedure he or she is to perform. For example, in vascular surgery, 
the suture size can range from as large as 3-0 (300-339 um) for use on the aorta to as 
small as 7-0 (50-69 µm) for use on renal-visceral arteries based on the scale defined by 
the USP (United States Pharmacopeia; Rockville, MD). [3,4] 
 
1.2 Vascular Anastomosis 
During nearly every surgical procedure there is some occurrence of broken 
vasculature. In most cases, the broken vessels are small and insignificant enough that the 
surgeon can cauterize the vessel and allow self-healing. However, when major blood 
vessels are broken, vascular anastomosis, or ligation, is required to restore the patency of 
the vessel. Vascular anastomosis uses surgical sutures to reconnect broken blood vessels 
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either end-to-end, end-to-side or side-to-side as 
seen in Figure 1.  Although primarily used by 
vascular surgeons, this technique is also applied 
by a variety of surgical specialties such as 
cardiovascular, plastic and reconstructive, 
otolaryngology, and orthopaedic. [5,6] There 
are many procedures that may require a version 
of vascular anastomosis, some of which 
include: free-tissue transfer, vascular graft 
implantation, and bypass surgery. [5,7] The 
vessels that require this reconstruction can 
range in size from the large root of the aorta 
to very small vessels such as digital arteries 
which require microvascular anastomosis. [3] Some of the complications of vascular 
anastomosis include anastomotic thrombosis and stenosis caused by intimal hyperplasia 
which are consequences of the inherent injury to the vascular wall. 
 
1.3 Vascular Anastomosis Complications 
1.3.1 Anastomotic Thrombosis 
When vasculature is broken and subsequently reconnected with sutures by 
anastomosis, an inflammatory response occurs triggering the coagulation cascade. 
Although coagulation is the body’s natural response to injury, it can cause serious 





complications under certain 
circumstances. [6] The coagulation 
cascade leads to the development of a 
thrombus or blood clot within the vessel 
as seen in Figure 2.  This clot can cause 
the vessel to become occluded which 
typically occurs within 48 hours in 
approximately 80% of cases resulting in 
thrombotic occlusion. [8] A thrombus 
can also lead to the formation of an emboli, or mobile clot, which can cause serious co-
morbidities such as stroke. Anastomotic thrombosis is also known to be the leading cause 
of graft failure in free-tissue transfer procedures. Approximately 4 percent of free flaps 
and 10 to 30 percent of digital replantations experience failure due to thrombosis. [9,10] 
It is imperative that coagulation be prevented so that thrombosis does not occur at the site 
of injury during vascular anastomosis procedures. 
1.3.2 Intimal Hyperplasia and Vascular Stenosis 
Similar to anastomotic thrombosis, vascular stenosis - or narrowing of the vessel, 
occurs due to the onset of injury to the vascular wall. This damage leads to a chronic 
inflammatory response causing platelet aggregation and an infiltration of leukocytes. A 
biochemical imbalance then occurs and transforms the vascular smooth muscle cells 
(VSMCs) from the native contractile state to a myoproliferative state. The VSMCs begin 
Figure 2. Illustration of a thrombus formation 




to proliferate in the media of the 
vessel wall. Eventually, the VSMC 
proliferation migrates into the intima 
of the vessel thickening the arterial 
wall. [11]  
This thickening progression 
of the tunica intima is called intimal 
hyperplasia and it occurs throughout the first 18-months post-injury and eventually 
follows the same pathogenesis as atherosclerosis as seen in Figure 3. [3] Ultimately, 
intimal hyperplasia causes arterial stenosis, or narrowing of the vessel opening, 
restricting blood flow through the artery. Since approximately 50% of vein grafts and 
30% of all arterial bypass grafts fail due to vascular stenosis, it is vital that proliferation 
of VSMCs be inhibited to prevent intimal hyperplasia and stenosis following a vascular 
anastomosis procedure. [11] 
1.4 Anti-Coagulant Drugs 
Currently in vascular surgery, the gold standard for preventing thrombosis and 
improving vessel patency is the use of the anticoagulant drugs heparin, aspirin, and 
dextran. Most commonly used is the systemic delivery of heparin. Heparin is a highly 
sulfated glycosaminoglycan and is known to have an extremely high negative charge 
density. Heparin works by binding to and activating antithrombin III which then prevents 
thrombin from activating factors V, VIII and Xa in the coagulation cascade. This 
disruption ultimately prevents the formation of a thrombus. However, there are some 
Figure 3. Histology of vessel wall borrowed from MGH 




negative side-effects to the current systemic use of heparin such as uncontrolled bleeding, 
easy bruising and heparin-induced thrombocytopenia (HIT) putting the patient at risk of 
hemorrhage. [6] 
1.5 Anti-Proliferative Drugs 
More commonly known as a chemotherapy agent, paclitaxel (or Taxol), is also 
widely used as to prevent proliferation of VSMCs in vascular procedures such as balloon 
angioplasty or stent implantation. Paclitaxel is the structurally most complex member of 
the taxane family possessing a unique tetracyclic 17-carbon skeleton which can be seen 
in Figure 5. [12] Paclitaxel works by stabilizing polymerized microtubules and enhancing 
microtubule assembly which inhibits cell replication in the G0/G1 and G2/M phases of the 
cell cycle leading to cell death or apoptosis. [13] 
In addition to its anticoagulant effects, heparin has also known to inhibit the 
proliferation of VSMCs. Several theories for this have been studied, including the 
suppression of early VSMC genes, inhibition of production of matrix-degrading proteases 
that allow cell migration and proliferation, and the inhibition of mitogen-activated protein 
kinase. [11] 
1.6 Electrospinning 
1.6.1 General Electrospinning 
Over the last decade, a new fabrication technique called electrospinning has 
become increasingly popular in the biomedical field. The general appeal of this process 
stems from its low cost, easily customizable parameters, and simple one-step production 
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which has led to the exploration of its use in a variety of biomedical applications 
including surgical sutures. [2] 
Electrospinning uses an electrical field to draw a thin jet from a polymer-solution-
loaded capillary. Although setup configurations may vary depending on the application, 
the typical setup consists of a high voltage power source, a spinneret (i.e. syringe and 
needle), and a grounded collector. A polymer dissolved in a volatile solvent is loaded into 
a syringe with a blunt tip needle. When a voltage source is applied to the needle tip as the 
syringe slowly pumps out the polymer solution, the droplet is stretched toward the 
grounded collector due to an electrostatic repulsion that is counteracted by the surface 
tension as the solvent evaporates. At a critical point, a ‘Taylor cone’ forms causing a thin 
stream to erupt from the stretched droplet creating a nanofiber jet that dries in flight on its 
way to the grounded collector. [14,15] 
1.6.2 Electrospinning for Drug Delivery 
Electrospinning provides for a relatively simple and adaptable production of 
nanofibers which are appealing for drug delivery applications due to a high surface area 
to volume ratio, the potential for surface modification, flexibility in material selection, 
and a variety of drug loading methods. [16,17] The high surface area to volume ratio is 
particularly appealing for drug-delivery applications as it allows for a high drug-loading 
capacity. Additionally, the flexibility in material selection allows for the use of both 
biodegradable or non-degradable materials which can have a significant impact on the 




There are several methods currently used for incorporating a drug into the 
electrospinning process. The first method is simple drug loading where the drug is added 
to the polymer solution before fabrication of the nanofibers which usually exhibits a high 
loading efficiency. Another method is post-fabrication surface modification where the 
drug is either coated or immobilized onto the surface of the electrospun material.  This 
method is ideal for sensitive drugs that may involve proteins or DNA that cannot be 
subject to the volatile organic solvent or the high voltage applied during the 
electrospinning process. Co-axial and layer-by-layer techniques are also widely appealing 
for incorporating drugs with specific control over the release kinetics. Commonly in co-
axial electrospinning, a core of drug loaded polymer is surrounded by a sheath layer 
which is specifically designed to control the drug-release based on diffusion or 
degradation rates. [18] 
1.7 Current Approaches 
The use of electrospun nanofibers as a drug delivery system has become very 
popular among researchers – particularly as surgical sutures. In 2010 Hu et al. was able to 
fabricate electrospun braided antibiotic-loaded sutures that displayed antibacterial activity 
for up to 10 days with a low initial burst release followed by a sustained release profile 
which is ideal for prevention of infection as an initially high dose of antibiotics will help 
to kill any bacteria present in the wound. [19] 
A study done by Weldon et. al in 2012 successfully electrospun PLGA with the 
drug bupivacaine hydrochloride, a common local anesthetic, to create a local anesthetic-
eluting biodegradable suture. A release study showed that 100% of the drug was released 
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after 12 days and the in-vivo study demonstrated that analgesia was achieved one day 
after surgery and was sustained for one week in 90% of the animals. These results 
showed promise for the use of local anesthetics in sutures to prevent the use of post-
operative opioid analgesics.  [20] 
More recently, Padmakumar et. al electrospun drug-eluting sutures using the core-
sheath method in 2016. The drugs aceclofenac and insulin were incorporated into the 
poly-lactic-co-glycolic acid (PLGA) sheath which surrounded a poly-L-lactic acid 
(PLLA) core to demonstrate that both chemically and biologically active drugs can be 
electrospun into the suture. Their reasoning for using this core-sheath method was for the 
ability to incorporate the drugs into the suture for better loading efficiency and release 
kinetics compared to drug-coated sutures, but to maintain the strength with a 
mechanically robust core. Studies showed that sutures incorporated with aceclofenac and 
insulin allowed 15% and 4% loading and achieved release for ten and seven days 
respectively and both types of drug loaded sutures displayed effective therapeutic 
activity. [21] 
When it comes to mitigating thrombosis and stenosis following vascular injury, 
there are many approaches being explored. One of the most recent successes was the 
creation of drug-eluting stents which was first approved by the FDA in 2003. Most 
commonly, the drugs used in these stents are either sirolimus or paclitaxel which are both 
intended to combat post-stent restenosis caused by the excessive proliferation of VSMCs 
following endothelial injury, as discussed previously. [22] 
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In 2006, Luong-Van et. al. explored the idea loading heparin on the surface of 
electrospun poly(ε-caprolactone) mats in order to achieve sustained localized release of 
heparin at the site of grafted blood vessels to prevent VSMC proliferation. The group was 
able to homogenously load heparin throughout the electrospun mat and achieved 
approximately 50% release after 14 days. The electrospun mats were also successful at 
inhibiting the proliferation of VSMCs in-vitro. [11] 
These studies demonstrate a great potential for the use of electrospun drug-eluting 
sutures to locally address a variety of conditions such as surgical site infections, local 
anesthesia, and inflammation. Currently, Ethicon is the only company to successfully 
market a drug-loaded suture in the US. However, these sutures are extruded in a process 
similar to synthetic textiles and then coated with an antimicrobial agent. [2] This 
relatively new and untouched market continues to inspire researchers to develop drug-
eluting sutures to locally deliver therapeutics, and electrospinning shows great promise as 
a manufacturing method. 
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CHAPTER 2 – RESEARCH OBJECTIVE 
2.1 Research Rationale 
The overall goal of this research project is to develop a combination drug-eluting 
suture that will provide both anticoagulant and anti-proliferative effects at the local injury 
site of a vascular anastomosis procedure in order to combat anastomotic thrombosis and 
stenosis. The suture will be fabricated using electrospinning techniques and will 
incorporate the anticoagulant heparin and the anti-proliferative drug paclitaxel. The 
polymeric solution used for 
electrospinning will be composed of 
three polymers: poly(lactide-co-
glycolic acid) or PLGA, 
poly(ethylene oxide) or PEO, and the 
novel polyethylenimine-g-poly(D, L-
lactide-co-glycolide) or PgP. The polymer PgP is a cationic amphiphilic block copolymer 
and its chemical structure can be seen in Figure 4.  
It is hypothesized that heparin, a negatively charged molecule, will bind to the 
positively charged polyethylenimine or PEI block of the PgP copolymer. It is also 
anticipated that paclitaxel, a hydrophobic molecule, will bind to the hydrophobic block of 
Figure 4. PgP chemical structure 
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the PgP copolymer. A schematic representation of these interactions can be seen in 
Figure 5.  
Therefore, the incorporation of the novel PgP copolymer into the suture is expected to 
improve loading efficiency and provide sustained and controlled release of both heparin 
and paclitaxel in order to prevent thrombosis and stenosis. 
 Previously in the 4D lab, an electrospun fiber containing the PgP polymer was 
successfully fabricated and characterized. The PgP incorporated fibers were then 
immobilized with heparin and the loading efficiency and release kinetics were evaluated 
in comparison to non-PgP fibers in order to confirm the heparin-PEI electrostatic 
interaction. The yarns containing a higher presence of PEI showed increased loading 
efficiency as well as a slower, more sustained release of heparin over time. Therapeutic 
activity of the immobilized heparin was then investigated with an activated partial 
thromboplastin time (APPT) test. The test showed an increased clotting time for the 
Figure 5. Heparin molecules are electrostatically bound to the surface of the suture by the 
positive PEI block of the PgP copolymer and paclitaxel molecules are contained within the 
suture and interact with the negative, hydrophobic block of the PgP copolymer. 
12 
 
samples containing fibers loaded with more heparin. These positive results were the first 
step in preventing anastomotic thrombosis.  
2.2 Project Aims 
 In order to reach the overall project goal, both anastomotic thrombosis and 
stenosis must be addressed. By incorporating the anti-proliferative drug paclitaxel into 
the electrospun fibers, VSMC proliferation can be inhibited which will prevent intimal 
hyperplasia from occurring in the vessel wall. The next step of this project is to 
investigate the potential for paclitaxel-loaded electrospun fibers for vascular suture 
applications. This objective will be met by the following aims: 
Aim 1: Fabricate and characterize the mechanical properties of paclitaxel-loaded 
electrospun fibers. 
Aim 2: Evaluate the loading efficiency and release kinetics of paclitaxel from the 
electrospun fibers. 




CHAPTER 3 – MATERIALS & METHODS 
3.1 Materials 
Poly (lactic-co-glycolic acid) (PLGA) (50:50, 50kDa;50:50, 100kDa) was purchased 
from Durect Corporation (Cupertino, CA). Poly(ethylene oxide) (PEO) (1000kDa), 
anhydrous dimethylformamide (DMF), N-N-Dimethylacetamide (DMAc), N-
hydroxysuccidimide (NHS), dicyclocarbodiimide (DCC), branched polyethylenimine (b-
PEI) (25kDa) and Thiazolyl Blue Tetrazolium Bromide (MTT) were obtained from 
Sigma-Aldrich (St. Louis, MO). Dimethylsulfoxide (DMSO) and Acetonitrile (ACN) 
were obtained from Thermo Fisher Scientific (Waltham, MA). Paclitaxel was purchased 
from LC Labs (Woburn, MA). 
3.2 Synthesis of (polyethylenimine-g-poly (D,L-lactide-co-glycolide)) PgP 
PgP was synthesized using poly(lactic-co-clycolic acid) (PLGA) and branched 
polyethylenimine (PEI) at a 10:1 molar ratio of PLGA:PEI. Dimethylformamide (DMF) 
was dried overnight using a molecular sieve. To activate the carboxylic end group of 
PLGA,  N-hydroxysuccidimide (NHS) and dicyclocarbodiimide (DCC) were added to the 
PLGA solution and stirred at room temperature for 2 hours. A glass funnel with a fine 
pore size was used to filter the resulting precipitate, dicyclohexyl urea (DCU). The 
dissolved PEI solution was added dropwise to the activated PLGA filtrate solution for 30 
minutes and then stirred at room temperature for 24 hours to complete the reaction.  
The reaction solution was then transferred to dialysis membranes (MWCO=50,000) 
in deionized water for a total of 2 days. The water was removed and replaced at 2, 4, 6 
and 24-hour time points throughout the dialysis. The product was then centrifuged at 
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5,000 rpm for 10 minutes. The precipitate and supernatant were separated and freeze-
dried for analysis and use. The final structure of PgP was verified by dissolving 10 mg of 
product in 1 mL of deuterated DMSO (DMSO-d6) and using 
1H-NMR on a Bruker 
300MHz. 
 






3.3.1 General Electrospinning Setup 
The electrospinning setup used for 
this project was developed by Dr. 
Konstantin Kornev’s group and is 
maintained by Dr. Guzeliya 
Korneva. [23] The setup shown in 
Figure 7 consists of an automated 
syringe pump sitting on an 
adjustable platform (c), a 10mL 
Teflon coated syringe (a) coupled 
with a blunt tip needle (b) from which the polymer jet emerges, a high voltage power 
source (d) that is connected to the syringe needle by an alligator clip and is also grounded 
to the rotating mandrel collector (f). Although not shown in Figure 7, the syringe and part 
of the needle is wrapped with a heat sleeve set to 60⁰C in order to prevent the polymeric 
solution from solidifying during the electrospinning process. 
3.3.2 Polymer Solution Preparation 
There were four polymeric solutions used for electrospinning during this study 
which are described in Table 1. The electrospinning solutions were generally prepared by 
adding the required amount of PLGA (50:50,100kDa) to dimethylacetamide (DMAc) and 
stirring at room temperature until fully dissolved. PEO (1000kDa) was then added to the 
Figure 7. Illustration of electrospinning setup 
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solution along with heat (~60⁰C) until fully dissolved. When necessary, PgP and/or 
paclitaxel were dissolved separately in DMAc and then added to the fully dissolved and 
warmed PLGA/PEO solution.  
 
3.3.3 Electrospinning Process 
Once the desired polymer solution had fully dissolved, it was transferred to a pre-
warmed 10mL Teflon-wrapped syringe with a blunt tip needle. The polymer filled 
syringe was then placed in the syringe pump and wrapped in a heat sleeve set to 60⁰C. 
The positive voltage source was connected to the needle by an alligator clip and the 
negative voltage source was connected to the base of the custom made spinning mandrel 
to ground the collector. During the spinning process, the nanofibers were uniformly 
collected around the mandrel as seen in Figure 8(B) for one hour. After 30 minutes, the 
mandrel direction was reversed. The room temperature, humidity, gap distance, applied 
voltage, flow rate, spin time and twist time were recorded for each spin. To control the 
humidity, when necessary, the electrospinning setup was done within a custom made 
chamber connected to a humidifier as seen in Figure 8(A).  
  






Figure 8. Images of the electrospinning setup and rotating mandrel used in this study and 
step-by-step collection of electrospun nanofibers from the mandrel followed by the 




Table 2. List of parameters maintained during the electrospinning process. 
 
3.3.4 Collection of Nanofibers & Formation of Twisted Fiber Suture 
The aligned nanofibers were then collected using a custom made device which 
consisted of two round brushes which could be adjusted to the same inner distance 
between the mandrel arms Figure 9. 
The brushes were manually rolled from 
the bottom of the mandrel to the top 
collecting the fibers into a cylindrical 
web of nanofibers as seen in Figure 
8(C-E). The device was then connected 
to a powered motor that twisted the 
brushes in opposite directions at the same speed, forming a uniformly twisted fiber after 
30-60 seconds Figure 8(F-G). The fiber was then cut at each end and stored in a petri 
dish. This process was repeated for each side of the mandrel resulting in four fibers each 
batch. The fibers were placed in a desiccator for at least 24 hours before testing.  




3.4 Fiber Characterization 
3.4.1 Fiber Imaging 
After fabrication, phase contrast microscopy (Axiovert S100) was used to both 
visualize the fibers produced and measure the diameters. Images were taken at 10x 
magnification using ProgRes Capture Pro 2.10.0.1 at 15ms exposure. The diameter of the 
fiber was measured using iSolution software version 10.1 calibrated for micrometers. In 
order to obtain an accurate measurement, the diameter was measured at three different 
locations along the length of the fiber and the measurements were averaged. 
3.4.2 Mechanical Tensile Testing 
In order to determine the 
mechanical tensile properties of 
the electrospun fibers, an Instron 
5944 Material Testing Frame 
was used to perform tensile 
tests. Before testing, the fiber 
was cut into 5 cm segments and 
clamped into the grips on the 
machine with an approximate 
gauge length of 4 cm. Once the 
fiber was secured, the upper 
clamp was manually raised until 
the fiber was taught. This 
Figure 10. Instron during testing of electrospun fiber. 
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distance was measured and recorded in the software along with the fiber’s average 
diameter measured previously. Before the test was run, the load and the gauge distance 
was zeroed. The test was run using a 50N load cell under uniaxial tension at a rate of 5.0 
mm/min. Tests were run until the fiber failed.  
 The Bluehill 2 software provided by Instron output the raw data, a stress-strain 
curve, as well as calculations of Young’s Modulus, tensile stress at yield, tensile strain at 
yield, and load at yield for each sample tested. Based on the user’s discretion, a stress-
strain curve was created in Microsoft Excel from the raw data provided in order to obtain 
more accurate calculations of tensile properties such as Young’s Modulus. This was done 
by manually determining the slope of the linear plastic region of the stress-strain curve 
using Excel’s slope function. 
3.5 Paclitaxel Loading Quantification 
To determine the amount of paclitaxel that was successfully loaded into the 
electrospun fibers containing paclitaxel (PP+Pac and PPP3.7+Pac), small amounts of 
fibers of known mass were allowed to fully dissolve in DMSO for at least 4 hours. The 
resulting DMSO solution was filtered using 0.2 µm pore size filters and tested using High 
Performance Liquid Chromatography (HPLC) using a Waters 1525 Binary HPLC Pump 
and 2707 Autosampler. The HPLC method used to detect paclitaxel was adapted from 
S.C Kim et al. [12] A Waters Symmetry C18 column was used with a mobile phase of 
50:50 deionized water and HPLC grade acetonitrile with a gradient flow rate of 1.0 
mL/min. PDA (photodiode array) detection was performed at 227nm to obtain the 
absorbance peak for the paclitaxel. The injection volume was 50 µL which ran for 32 
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minutes, and the retention time for the paclitaxel peak was 19.3 minutes. In order to 
quantify the resulting peaks, they were first integrated and the areas were compared to the 
integrated peaks of the prepared standards of known paclitaxel concentrations in DMSO 
using a standard curve. The average sample concentration was converted to µg of 
paclitaxel per milligram of fiber based on the mass of the fiber dissolved. 
In order to determine the efficiency of the paclitaxel loading into the electrospun 
fibers, the amount of drug  loaded into the fiber must be compared to the total drug 
originally dissolved in the electrospinning solution. The ratio of drug to fiber determined 
by the loading study was divided by the ratio of total drug dissolved to total polymer 
dissolved in the electrospinning solution which provided the drug loading efficiency. 
3.6 Paclitaxel Release Study 
Once the amount of paclitaxel loaded into the PP+Pac and PPP3.7+Pac fibers was 
known, the release kinetics of the drug from the electrospun fibers were investigated. 
Approximately 5 mg of each fiber type was added to 1 mL of phosphate buffered saline 
(PBS) and incubated at 37⁰C to simulate physiologic conditions. At 0, 1 hour, 2 hours, 4 
hours, 8 hours, 24 hours and every day for 7 days, the PBS solution was removed from 
the fibers and placed in a -80⁰C freezer. Fresh PBS was then added back onto the fiber 
and returned to the incubator until the next time point.  
Before testing, the samples were removed from the freezer and lyophilized for 48 
hours. Once freeze-dried, the samples were centrifuged, re-suspended in 250 µL of 
DMSO and centrifuged again at 10,000 rpm for 5 minutes. The supernatant was then 
removed and filtered using a 0.2 µm filter in order to test the sample with HPLC. The 
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same HPLC methods discussed previously were used to determine the amount of 
paclitaxel released. PPP3.7 fibers not containing paclitaxel and PBS alone were used as 
controls to ensure that no peak would be detected without the presence of paclitaxel. 
Each type of fiber was tested in triplicate. 
3.7 VSMC Proliferation Inhibition Assay 
To ensure that the activity of the paclitaxel loaded in the electrospun fibers was not 
compromised during the electrospinning process, a proliferation inhibition assay was 
performed on primary rat vascular smooth muscle cells (VSMCs) adapted from Luong-
Van et. al. [11] The cultured VSMCs were plated at approximately 1x104 cells/cm2 in 
complete DMEM media containing 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomyosin (pen/strep) and allowed to attach for 24 hours. The VSMCs were 
then serum starved in DMEM media containing 1% FBS and 1% pen/strep for 72 hours. 
Based on the results from the loading study fibers were weighed out to contain 
approximately 2 µg of paclitaxel. The pre-weighed fibers were sterilized by rinsing two 
times in sterile deionized water and were added to the wells with the cells along with 
complete DMEM containing 10% FBS 1% pen/strep.  Untreated cells were used as a 
control. Cells treated with PPP3.7 fibers without paclitaxel and cells treated with free 
paclitaxel dissolved in DMSO added at a concentration of 0.3 µg/mL based on the results 
from the release study were used for comparison.  
After three days, cell proliferation inhibition was tested using a MTT assay.  The 
media and fibers from each well were removed and then 12.5 µL of 2 mg/mL Thiazolyl 
Blue Tetrazolium Bromide (MTT) in PBS reagent along with 200 µL of media were 
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added into each well. The cells were then incubated for 4 hours to allow the conversion 
of MTT into formazan crystals by the metabolically live cells. The media with MTT 
reagent was then removed and replaced with 100 µL DMSO to dissolve the crystals. The 
plate was read by a Biotek Synergy4 multi-detection plate reader to determine the 
absorbance of each well. The absorbance values were then compared to the averages of 
the positive and negative controls to determine the percent of growth inhibition on the 
VSMCs. 
3.8 Data and Statistical Analysis 
The data presented for mechanical testing, drug loading, loading efficiency, drug 
release and therapeutic activity are given as means ± standard error of the mean (SEM). 
All statistical analysis was assessed with one-way ANOVA followed by a Turkey post-





CHAPTER 4 – RESULTS & DISSCUSION 
4.1 Synthesis and Characterization of PgP Polymerization 
 PgP 3.7 was successfully synthesized using the molar ratios of PLGA and bPEI 
(10:1). The structure of PgP and the grafting ratio of PLGA to bPEI were verified by 1H-
NMR (DMSO-d6) (δ = 1.47 (3H, PLGA –CH3), δ = 3.2–3.7 (PEI backbone –CH2CH2–), 
δ = 4.9 (2H, PLGA –CH2), δ = 5.2 (1H, PLGA –CH)).  The ratio of the integrals of the 
PEI backbone (δ = 3.4) to the methine of PLGA (δ = 5.2) demonstrated that 
approximately 3.7 PLGA molecules were grafted to 1 bPEI molecule and molecular 
weight of PgP1 was about 210,000 Figure 11. 
  





The polymers selected for this application were chosen based on a number of 
factors. The polymer PLGA is not only FDA approved for use in commercially available 
sutures, but it is also biodegradable and soluble in multiple solvents commonly used for 
electrospinning. [17,24,25] A high molecular weight PLGA with an inherent viscosity of 
0.95-1.20 dL/g was chosen for several reasons. Using a higher molecular weight polymer 
will not only benefit the mechanical strength of the fibers, but is also shown to slow 
degradation rates compared to polymers with lower molecular weights. [26] Decreasing 
degradation rate is extremely beneficial when trying to achieve slow and sustained drug 
release. [27] An increased solution viscosity is also shown to improve electrospin-ability 
and produce nanofibers of more uniform diameters. [17] A small amount of high 
molecular weight Poly(ethylene oxide) (PEO) was also added to the solution help 
improve the spin-ability of the PLGA in the presence of PgP3.7. [28] 
The solvent selection for an electrospinning application is very important to the 
spin-ability of the solution. The solvent DMAc was chosen for this application for 
multiple reasons. PLGA was able to dissolve in the solvent at room temperature in a 
relatively short period of time (1-2 hours) and in an even shorter period of time when 
heated at ~60⁰C (10-20 min). DMAc was also able to dissolve PgP3.7 which does not 
readily dissolve in most solvents. However, PEO would not dissolve in the solvent at 
room temperature, but was able to dissolve when heated to ~60⁰C. Once PEO was 
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dissolved, the solution would solidify when cooled to room temperature, so constant heat 
was applied to the solution using a heat sleeve over the syringe during electrospinning. 
As stated previously, there are a variety of parameters than can affect the quality 
of electrospinning such as humidity, temperature, flow rate, applied voltage and distance 
from needle to collector. The parameters listed in Table 2 were maintained as consistently 
as possible for each batch of fibers produced. The most challenging parameter to 
maintain was the relative humidity. Particularly in the winter when the humidity dropped 
below 50% (sometimes as low as 20%), it was nearly impossible to produce a consistent 
polymer stream. In these circumstances, the insulated box was connected to a humidifier 




4.3 Electrospun-Fiber Characterization 
4.3.1 Surface Morphology of Paclitaxel-Loaded Electrospun Fibers 
The phase contrast microscopy images in Figure 12 show the general appearance 
of the electrospun fibers produced with and without paclitaxel. Both fiber types seem to 
have similar diameters and shape as well as a considerable amount of stray fibers 
extending from the surface. This is likely explained by the electrostatic nature of the 
individual nanofibers caused by an imbalance of positive and negative charges. During 
the collecting and twisting process, the nanofibers are easily attracted to any approaching 
object due to electrostatic interactions causing some to stray from the alignment along the 
length of the mandrel. Further investigation into the surface morphology using more 
powerful imaging technology such as scanning electron microscopy (SEM) imaging 
Figure 12. Phase contrast microscopy images of PPP3.7 and 
PPP3.7+Pac fibers at 10x objective magnification. 
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should be pursued in future studies as well as investigating potential solutions to reduce 
the stray nanofibers during the fiber fabrication process. 
The diameters of each fiber were also determined and are listed in Table 3. These 
diameters fall between USP absorbable suture sizes 4-0 (150-199 µm) and 3-0 (200-249 
µm) which are both commonly used for large vessels such as the aorta, however would 
be on the large side for anastomosis of smaller vessels which usually require sizes 5-0 
(100-149 µm) to 7-0 (50-69 µm). [4] There was often slight variation in the diameter of 
fibers within and between batches. This is likely due to minor deviations in 
electrospinning parameters such as humidity, applied voltage, and spin time. 
 
4.3.2 Mechanical Properties of Paclitaxel-Loaded Electrospun Fibers 
When determining the mechanical properties of surgical sutures, there are two 
main tensile tests used: straight-pull and knot-pull. Based on testing performed in similar 
literature, straight-pull tensile testing was used for this study since it provides a better 
understanding of the overall mechanical behavior. The mechanical properties of each 
type of fiber are provided in Table 3 which are also illustrated in graphical form in Figure 
13 with statistical analysis presented. Fibers containing PgP3.7 seemed to perform better 
than those without in most of the mechanical property categories. As seen in Figure 
Table 3. Mechanical properties of each type of electrospun fiber. Data given as Mean ± SEM. 
29 
 
13(A,B,D) the tensile strength, peak load and modulus of PPP3.7 fibers and PPP3.7 fibers 
containing paclitaxel (PPP3.7+Pac) were significantly different from non-PgP fibers with 
p-values less than 0.0001 and at least less than 0.05, respectively. This evidence suggests 
that the incorporation of PgP3.7 into the electrospun fibers has a significant positive 
impact on the mechanical properties. The tensile strength, peak load and modulus of the 
PPP3.7 fibers was also significantly different from the paclitaxel containing fiber of the 
same composition (PPP3.7+Pac) with a p-value less than 0.0001. According to a study 
done by C. Johnson et. al in 2016, the incorporation of a drug into electrospun fibers has 
a significant effect on the physical characteristics of the fibers. This is suggested to be 
due to smaller diameter nanofiber production and lower alignment of nanofibers collected 
which could explain why fibers containing paclitaxel did not perform as well 
mechanically as fibers of the same composition without the drug incorporation. [14] With 
further investigation into the surface morphology of the electrospun fibers using more 
advanced imaging methods as suggested previously, it could be determined whether or 
not the diameter and alignment of the nanofibers within the paclitaxel containing fibers 





Figure 13. Tensile properties of electrospun fibers: (A) Tensile strengths; ****=p<0.0001 
compared to PP and PP+Pac, ####=p<0.0001 compared to PPP3.7+Pac (B) Peak load values; 
****=p<0.0001 and **=p<0.01 both compared to PP and PP+Pac, ####=p<0.0001 compared 
to PPP3.7+Pac (C) Percent elongation values; **=p<0.01 and *=p<0.05 both compared to 
PP+Pac (D) Young’s Modulus values; ****=p<0.0001 and **=p<0.01 both compared to PP 




It must also be noted that even the PPP3.7 fibers with an average tensile strength 
of approximately 23 MPa, elastic modulus of nearly 900 MPa and peak load of 0.45 N 
are much weaker than both comparable commercially available sutures and knot-pull 
strengths required by the USP for sutures of similar size. Ethicon’s Vicryl® sutures, also 
composed of PLGA, have minimum tensile strength and elastic modulus requirements of 
410 MPa and 1,400 MPa, respectively. [29] The USP required knot-pull strength for size 
4-0 synthetic sutures is 9.32 N, more than twenty times greater than PPP3.7 electrospun 
fibers.  
Isolated stress-strain curves for each fiber type were compiled and over-laid in 
Figure 14 to demonstrate that although some of the mechanical properties vary between 
each fiber type, the trend in elastic and plastic regions is similar indicating the ductility of 
the fibers remains consistent.  
 
  Figure 14. Stress-strain curves of each type of electrospun fiber 
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4.4 Paclitaxel Loading of Electrospun Fibers 
Since paclitaxel has shown to be therapeutically active at concentrations as low as 
0.05 µg/mL, a sensitive detection method such as HPLC (high performance liquid 
chromatography) must be used for pharmacokinetic analysis. [12] Before testing the 
samples, a series of standard curves with known concentrations of paclitaxel dissolved in 
DMSO ranging from 0.001 µg/mL to 10 µg/mL were run through the HPLC column to 
determine the detection limit. Below a concentration of 0.25 µg/mL, the PDA 
(photodiode array) was unable to detect an absorbance peak.  
During the electrospinning solution preparation, approximately 2 mg of paclitaxel 
was dissolved in either 15% PLGA [450 mg] 1% PEO [30 mg] (PP+Pac) or 15% PLGA 
[450 mg] 1% PEO [30 mg] 0.067% PgP3.7 [2 mg] (PPP3.7+Pac) in 3 mL DMAc as 
outlined in Table 1. Therefore, there is theoretically 1 mg of paclitaxel for every 240 mg 
of polymer (approx. 4.17 µg paclitaxel per mg polymer). Since the detection limit of 
paclitaxel in DMSO was approximately 0.25 µg/mL, a relatively small mass of fiber 
could be dissolved in DMSO to prepare an expected concentration of 2 µg/mL. The 
results for the loading evaluations are given in Table 4 and are also presented graphically 
in Figure 15 with statistical analysis.  





Figure 15. Drug loading evaluations: (A) Amount of paclitaxel loaded per mg of electrospun 
fiber. (B) Percent of paclitaxel loaded into the electrospun fiber compared to the total amount of 
paclitaxel added to the electrospinning solution. *=p<0.05 compared to PP+Pac. Data is 
presented as Mean ± SEM.  
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 According to these results, electrospun fibers containing PgP3.7 were statistically 
able to load more paclitaxel per milligram of fiber and were also more efficient at loading 
paclitaxel compared to fibers without. These results support our hypothesis that the 
hydrophobic region of PgP3.7 will bind to the hydrophobic drug paclitaxel, increasing 
loading efficiency of the electrospun fiber. 
4.5 Paclitaxel Release Kinetics 
The release profile of paclitaxel from the electrospun yarns over 24 hours and 7 days 
are provided in Figure 16. During the first 24 hours, both fibers demonstrated slow and 
sustained release kinetics with only around 7.5% released from PP+Pac and 10.6% 
released from PPP3.7+Pac. After 7 days, the release pattern is still slow and sustained 
with less than 15% and 20% of paclitaxel released from PP+Pac and PPP3.7+Pac 
respectively. Although the highest rate of VSMC proliferation occurs within the first 7 
days, it is shown to continue for as long as 14-28 days depending on the severity of 
injury. [11] If this release pattern were to continue at this rate, small concentrations of 
paclitaxel could be released from the fiber for more than 30 days. It is noted that there 
seems to be a peak in release between 4 and 5 days, this is possibly due to slight 
variations in collection time from day-to-day and small sample population. With the 
addition of more data points this will likely smooth out. 
Electrospun fibers containing PgP3.7 released slightly more paclitaxel than those 
without which is expected due to the higher loading capacity of PgP3.7 containing fibers 
discussed previously. Since more palclitaxel was loaded into these fibers, they would 





Figure 16. Drug release profiles of PPP3.7, PP+Pac and PPP3.7+Pac electrospun fibers over 
(A) 24 hours and (B) 7 days. *=p<0.05 compared to PP+Pac using 2-tailed t-test. Data 
presented as Mean ± SEM.  
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4.6 Therapeutic Activity of Paclitaxel-Loaded Fibers 
In order to prevent intimal hyperplasia from occurring and causing stenosis of the 
vessel following anastomosis, proliferation of VSMCs must be inhibited. After treating 
the VSMCs for 3 days with PPP3.7 fibers, PPP3.7+Pac fibers and paclitaxel alone, the 
percent growth inhibition was determined and the results are shown in Figure 17. All 
three treatments were significantly different compared to untreated cells. The 
PPP3.7+Pac fibers, which inhibited approximately 40% of growth, were significantly 
different compared to both untreated cells and PPP3.7 not containing paclitaxel. This 
Figure 17. Therapeutic activity of electrospun fibers and controls on VSMCs treated for 3 
days. ****=p<0.0001 and *=p<0.05 both compared to untreated VSMCs, #=p<0.05 
compared to PPP3.7. The paclitaxel alone group contained 0.3 µg/mL paclitaxel.  
Mean ± SEM. 
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indicates that the drug was able to maintain therapeutic activity throughout the 
electrospinning process.  
It is noted that there is still a slight inhibitory effect on the growth of VSMCs by 
electrospun fibers not containing paclitaxel. There are two possible explanations for this 
to occur. First, the fibers were placed directly into the wells on top of the cell layer which 
could cause cell death. This could be avoided in future studies by either conditioning the 
media with the fiber treatments or by using transwell inserts to prevent the fibers from 
physically disturbing the cells. Secondly, the sterilization process for the fibers may not 






CHAPTER 5: CONCLUSION 
The goal of this project was to determine the feasibility of incorporating paclitaxel 
into electrospun fibers containing PgP3.7 to be used as vascular sutures than can locally 
inhibit the proliferation of VSMCs and ultimately prevent intimal hyperplasia and 
stenosis following anastomosis procedures. The first aim to successfully fabricate and 
characterize the electrospun fibers containing both PgP and paclitaxel was met and 
confirmed by fiber imaging and mechanical testing which showed uniform fiber 
formation with minimal defects and consistent ductile mechanical properties for each 
electrospun fiber type. However, the mechanical strength of the electrospun fibers was 
nearly twenty times lower than commercially available sutures. 
The second aim of this project was to determine the loading efficiency and release 
kinetics of the paclitaxel-loaded electrospun fibers. The hypothesis was confirmed that 
electrospun fibers containing PgP3.7 were able to load significantly more paclitaxel with 
greater loading efficiency compared to those without due to the large hydrophobic region 
of the PgP3.7 binding to the hydrophobic drug. Congruently, the release profiles of both 
PgP3.7 and non-PgP3.7 paclitaxel loaded electrospun fibers demonstrated a slow and 
sustained release profile with slightly more drug released over time from PgP3.7 
containing fibers. 
The third and final aim of this project was to ensure that the therapeutic activity of 
paclitaxel was not compromised during the electrospinning process. This was done in-
vitro by culturing primary VSMCs and treating them for three days with electrospun 
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fibers containing paclitaxel and comparing the growth inhibitory effects to untreated 
cells, non-drug-loaded electrospun fibers and paclitaxel alone. The results showed that 
paclitaxel loaded fibers had significantly more inhibitory effects when compared to 
untreated cells. 
In conclusion, all three aims of this study were met and the results were very 
promising for the potential use of paclitaxel loaded electrospun fibers as sutures to 




CHAPTER 6: LIMITATIONS AND FUTURE STUDIES 
 Moving forward with this project, it is important to consider the overall goal 
which is to develop a dual-drug-eluting vascular suture to combat both thrombosis and 
stenosis following an anastomosis procedure. Previously in the 4D lab, the fabrication 
and characterization of electrospun heparin-immobilized sutures was successfully 
completed to address the issue of thrombosis and also to assist in inhibition of VSMC 
proliferation. In the future, steps should be taken to combine both paclitaxel incorporated 
electrospun fibers and heparin-immobilization and test the potential sutures in-vivo with a 
rat vein anastomosis model. 
 One of the major limitations of this project is the mechanical strength of the 
electrospun fibers compared to commercially available vascular sutures. There are 
several potential solutions that can be explored. The first would be to attempt the core-
sheath method of electrospinning where the paclitaxel and PgP3.7 incorporated polymer 
mixture could surround a more mechanically robust polymeric core such as 
polycaprolactone (PCL) or poly-L-lactic acid (PLLA) similar to the study done by 
Padmakumar et. al. [21] This method would still allow for the slow and sustained release 
of paclitaxel and the surface exposure of PgP3.7 for heparin immobilization since the 
biological drug heparin cannot be subjected to the volatile solvent and high voltage 
during electrospinning, but may provide additional mechanical support by the core. 
Another option to pursue would be another more traditional fabrication technique such as 
melt extrusion where both drugs could be incorporated directly into the fiber, but the 
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